Harel Insurance Investments & Financial Services Ltd. lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 25.7% during the second quarter, Holdings Channel reports. The institutional investor owned 11,620 shares of the medical equipment provider’s stock after selling 4,013 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Boston Scientific Corporation were worth $322,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. BlackRock Inc. raised its stake in Boston Scientific Corporation by 2,181.6% in the first quarter. BlackRock Inc. now owns 95,744,545 shares of the medical equipment provider’s stock worth $2,381,169,000 after buying an additional 91,548,235 shares during the period. FMR LLC raised its stake in Boston Scientific Corporation by 7.6% in the first quarter. FMR LLC now owns 184,708,390 shares of the medical equipment provider’s stock worth $4,593,698,000 after buying an additional 13,105,596 shares during the period. MARSHALL WACE ASIA Ltd purchased a new stake in Boston Scientific Corporation during the first quarter worth $149,859,000. Marshall Wace North America L.P. purchased a new stake in Boston Scientific Corporation during the first quarter worth $149,859,000. Finally, Vanguard Group Inc. raised its stake in Boston Scientific Corporation by 4.0% in the first quarter. Vanguard Group Inc. now owns 91,134,744 shares of the medical equipment provider’s stock worth $2,266,521,000 after buying an additional 3,503,965 shares during the period. Hedge funds and other institutional investors own 92.08% of the company’s stock.

Boston Scientific Corporation (NYSE:BSX) opened at 26.26 on Friday. The stock’s 50 day moving average is $27.38 and its 200-day moving average is $26.02. The company has a market capitalization of $36.03 billion, a P/E ratio of 46.98 and a beta of 1.09. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $28.51.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.01. The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The business’s revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.27 EPS. On average, analysts expect that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Harel Insurance Investments & Financial Services Ltd. Sells 4,013 Shares of Boston Scientific Corporation (BSX)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/harel-insurance-investments-financial-services-ltd-sells-4013-shares-of-boston-scientific-corporation-bsx/1474152.html.

BSX has been the topic of a number of recent analyst reports. Needham & Company LLC increased their price objective on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, June 22nd. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Boston Scientific Corporation in a research report on Wednesday, June 28th. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Boston Scientific Corporation in a research report on Tuesday, May 16th. They issued a “neutral” rating and a $28.00 price objective on the stock. Zacks Investment Research lowered shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, BidaskClub lowered shares of Boston Scientific Corporation from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $30.06.

In other news, EVP Timothy A. Pratt sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $27.13, for a total value of $271,300.00. Following the sale, the executive vice president now directly owns 215,846 shares of the company’s stock, valued at approximately $5,855,901.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Wendy Carruthers sold 12,433 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $26.75, for a total transaction of $332,582.75. The disclosure for this sale can be found here. Insiders sold a total of 236,489 shares of company stock worth $6,440,888 over the last three months. Insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.